378 related articles for article (PubMed ID: 31959133)
21. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
22. Clonal evolution of glioblastoma under therapy.
Wang J; Cazzato E; Ladewig E; Frattini V; Rosenbloom DI; Zairis S; Abate F; Liu Z; Elliott O; Shin YJ; Lee JK; Lee IH; Park WY; Eoli M; Blumberg AJ; Lasorella A; Nam DH; Finocchiaro G; Iavarone A; Rabadan R
Nat Genet; 2016 Jul; 48(7):768-76. PubMed ID: 27270107
[TBL] [Abstract][Full Text] [Related]
23. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
24. Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide.
Rahman R; Trippa L; Alden S; Fell G; Abbasi T; Mundkur Y; Singh NK; Talawdekar A; Husain Z; Vali S; Ligon KL; Wen PY; Alexander BM
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):716-724. PubMed ID: 32417407
[TBL] [Abstract][Full Text] [Related]
25. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
27. Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
Feldheim J; Kessler AF; Feldheim JJ; Schulz E; Wend D; Lazaridis L; Kleinschnitz C; Glas M; Ernestus RI; Brandner S; Monoranu CM; Löhr M; Hagemann C
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563629
[TBL] [Abstract][Full Text] [Related]
28. Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma.
Georgescu MM; Olar A
Acta Neuropathol Commun; 2020 Feb; 8(1):10. PubMed ID: 32014051
[TBL] [Abstract][Full Text] [Related]
29. A case study of a long-term glioblastoma survivor with unmethylated
Jue TR; Olafson LR; Siddell AH; Rapkins RW; Ng B; Yin JXM; Lu VM; Chung SA; Whittaker SP; Davies M; Fairhall JM; Hovey EJ; McDonald KL
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160353
[TBL] [Abstract][Full Text] [Related]
30. Progranulin promotes Temozolomide resistance of glioblastoma by orchestrating DNA repair and tumor stemness.
Bandey I; Chiou SH; Huang AP; Tsai JC; Tu PH
Oncogene; 2015 Apr; 34(14):1853-64. PubMed ID: 24793792
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic pathways and glioblastoma treatment.
Clarke J; Penas C; Pastori C; Komotar RJ; Bregy A; Shah AH; Wahlestedt C; Ayad NG
Epigenetics; 2013 Aug; 8(8):785-95. PubMed ID: 23807265
[TBL] [Abstract][Full Text] [Related]
32. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
33. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
Wick W; Dettmer S; Berberich A; Kessler T; Karapanagiotou-Schenkel I; Wick A; Winkler F; Pfaff E; Brors B; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Eisenmenger A; von Deimling A; Jones DTW; Pfister SM; Sahm F; Platten M
Neuro Oncol; 2019 Jan; 21(1):95-105. PubMed ID: 30277538
[TBL] [Abstract][Full Text] [Related]
34. Creutzfeldt astrocytes may be seen in IDH-wildtype glioblastoma and retain expression of DNA repair and chromatin binding proteins.
Ballester LY; Boghani Z; Baskin DS; Britz GW; Olsen R; Fuller GN; Powell SZ; Cykowski MD
Brain Pathol; 2018 Nov; 28(6):1012-1019. PubMed ID: 29509313
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
[TBL] [Abstract][Full Text] [Related]
36. The clinical characteristics and prognostic factors of multiple lesions in glioblastomas.
Tunthanathip T; Sangkhathat S; Tanvejsilp P; Kanjanapradit K
Clin Neurol Neurosurg; 2020 Aug; 195():105891. PubMed ID: 32480195
[TBL] [Abstract][Full Text] [Related]
37. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
38. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
[TBL] [Abstract][Full Text] [Related]
39. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive genetic alteration profiling in primary and recurrent glioblastoma.
Neilsen BK; Sleightholm R; McComb R; Ramkissoon SH; Ross JS; Corona RJ; Miller VA; Cooke M; Aizenberg MR
J Neurooncol; 2019 Mar; 142(1):111-118. PubMed ID: 30535594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
